Using corporate revenue reports, hospital billing data, leaked reimbursement contracts and interviews with insiders, the investigation sought an answer to a critical question: Why are life-saving medicines still out of reach for so many in Europe?
Using corporate revenue reports, hospital billing data, leaked reimbursement contracts and interviews with insiders, the investigation sought an answer to a critical question: Why are life-saving medicines still out of reach for so many in Europe?
In an unprecedented investigation, the team calculated estimated prices for critical drugs in nine EU countries, exposing how pharmaceutical giants exploit opaque pricing systems, lobbying power and intellectual property rules to keep drug costs high across the continent.
The jury commended the team behind Deadly Prices for exposing inequalities in Europe that affect the lives of millions of people.
“Deadly Prices is an influential investigation that revealed how pharmaceutical companies exploit Europe’s fragmented pricing system, leaving patients in smaller countries without access to life-saving treatments,” jury member Milosevic said.